NRIX Live signals | Maximize Profits with Getagraph.com

BUY 116059 min ago

@ $9.02

Issued: 14 Feb 2024 @ 14:04

Return: 41.69%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: 0.89 %

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 16:00):

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders...

Stats
Today's Volume	465 539
Average Volume	1.07M
Market Cap	758.08M
EPS	$0 ( 2024-04-11 )
Next earnings date	( $-0.720 ) 2024-07-11
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.80
ATR14	$0.0170 (0.13%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-02	Van Houte Hans	Sell	3 499	Common Stock
2024-04-30	Van Houte Hans	Buy	2 000	Common Stock
2024-04-30	Van Houte Hans	Sell	1 387	Common Stock
2024-04-30	Van Houte Hans	Buy	2 886	Common Stock
2024-04-30	Van Houte Hans	Sell	2 886	Restricted Stock Units

INSIDER POWER
90.20
Last 100 transactions
Buy: 2 500 607 \| Sell: 112 812

Volume Correlation

Long: -0.26 (neutral)

Short: 0.33 (neutral)

Signal:(56.837) Neutral

Nurix Therapeutics, Inc. Correlation

10 Most Positive Correlations
KELYA	0.934
HOOD	0.931
FCYIX	0.928
AIRR	0.925
VSEC	0.924
HSKA	0.923
NXGN	0.923
TTD	0.918
APLT	0.917
TRVI	0.916

10 Most Negative Correlations
SSP	-0.919
BRQS	-0.908
PEAR	-0.907
DCRC	-0.899
CYAN	-0.897
MFIN	-0.897
VORB	-0.894
LTRX	-0.892
SOFO	-0.891
PYR	-0.883

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nurix Therapeutics, Inc. Correlation - Currency/Commodity

-0.70
( moderate negative )

-0.69
( moderate negative )

0.00
( neutral )

-0.71
( moderate negative )

0.46
( neutral )

Nurix Therapeutics, Inc. Financials

Annual	2023
Revenue:	$76.99M
Gross Profit:	$63.33M (82.26 %)
EPS:	$-2.65

FY	2023
Revenue:	$76.99M
Gross Profit:	$63.33M (82.26 %)
EPS:	$-2.65

FY	2022
Revenue:	$38.63M
Gross Profit:	$27.82M (72.02 %)
EPS:	$-3.42

FY	2021
Revenue:	$29.75M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-2.64

Financial Reports:

No articles found.

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.